Progress of Non-Factor Products in Hemophilia Treatment--Review.
10.19746/j.cnki.issn.1009-2137.2022.04.054
- Author:
Jing-Jing LIANG
1
;
Lin-Hua YANG
2
Author Information
1. Department of Hematology, Second Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China.
2. Department of Hematology, Second Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China.E-mail: Yanglh5282@163.com.
- Publication Type:Review
- Keywords:
Concizumab;
Emicizumab;
Fitusiran;
non-factor product;
serpin
- MeSH:
Antibodies, Monoclonal, Humanized/adverse effects*;
Factor VIII/therapeutic use*;
Hemophilia A/therapy*;
Humans
- From:
Journal of Experimental Hematology
2022;30(4):1301-1304
- CountryChina
- Language:Chinese
-
Abstract:
Traditional replacement therapy is the main treatment method of hemophilia, while inhibitor generation makes replacement therapy ineffective. The emergence of non-factor therapy brings new hope for the treatment of patients with inhibitor. Non-factor products mainly achieve therapeutic purpose by imitating the function of coagulation factor Ⅷ, inhibiting the function of anti-tissue factor pathway inhibitors, the expression of antithrombin mRNA, and the function of activated protein C. This paper reviews the latest research progress of non-factor products in the treatment of hemophilia.
